Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 10:24 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 1,750 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Uterine Neoplasms Clear all
Completed Phase 1 Interventional

Study of STRO-002, an Anti-Folate Receptor Alpha (FolRα) Antibody Drug Conjugate in Ovarian & Endometrial Cancers

NCT03748186
View directory record Official record
Conditions
Ovarian Cancer, Ovarian Carcinoma, Ovary Cancer, Endometrial Cancer, Endometrioid Adenocarcinoma, Fallopian Tube Cancer, Primary Peritoneal Carcinoma
Interventions
STRO-002
Drug
Lead sponsor
Sutro Biopharma, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
23
States / cities
Tucson, Arizona • Los Angeles, California • San Francisco, California + 19 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2025 · Synced Oct 22, 2026, 10:24 PM EDT
Active, not recruiting No phase listed Observational

A Pilot Study of Quantitative Tumor Oxygen Measurements in Cervical Cancer

NCT03970083
View directory record Official record
Conditions
Gynecologic Cancer, Cervical Cancer
Interventions
Not listed
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older · Female only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 22, 2026 · Synced Oct 22, 2026, 10:24 PM EDT
Completed Not applicable Interventional Results available

Supportive Programs for Supporting Optimal Recovery in Participants Undergoing Gynecological Surgery

NCT03681405
View directory record Official record
Conditions
Ovarian Neoplasm, Uterine Neoplasm
Interventions
Informational Intervention, Questionnaire Administration, Telephone-Based Intervention
Other · Behavioral
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older · Female only
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 8, 2021 · Synced Oct 22, 2026, 10:24 PM EDT
Terminated Phase 3 Interventional Results available

Assess Safety and Efficacy of Vilaprisan in Subjects With Uterine Fibroids

NCT03194646
View directory record Official record
Conditions
Uterine Fibroids
Interventions
Vilaprisan (BAY1002670), Standard of care
Drug · Other
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older · Female only
Enrollment
1,272 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
94
States / cities
Birmingham, Alabama • Mobile, Alabama • Tucson, Arizona + 76 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2025 · Synced Oct 22, 2026, 10:24 PM EDT
Recruiting No phase listed Observational

Sample Collection for Ongoing Research and Product Evaluation Study

NCT07318051
View directory record Official record
Conditions
Breast Cancer, Lung Cancer, Muscle Invasive Bladder Cancer, Rectal Cancer, Pancreatic Cancer, Ovarian Cancer, Gastroesophageal Cancer, Prostate Cancer, Melanoma, Head and Neck Cancer, Uterine Cancer, Liver Cancer
Interventions
Not listed
Lead sponsor
Natera, Inc.
Industry
Eligibility
18 Years and older
Enrollment
9,600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2035
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jan 15, 2026 · Synced Oct 22, 2026, 10:24 PM EDT
Recruiting No phase listed Observational

A Multicenter Cancer Biospecimen Collection Study

NCT04510129
View directory record Official record
Conditions
Cancer of Head and Neck, Lung Cancer, Nonsmall Cell, Small-cell Lung Cancer, Urothelial Carcinoma, Gastroesophageal Junction Adenocarcinoma, Cervical Cancer, Esophageal Squamous Cell Carcinoma, Triple Negative Breast Cancer, Hepatocellular Carcinoma, Renal Cell Carcinoma, Colorectal Cancer
Interventions
OncoPrism™ assay
Diagnostic Test
Lead sponsor
Cofactor Genomics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,650 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Mar 12, 2025 · Synced Oct 22, 2026, 10:24 PM EDT
Completed Phase 2 Interventional Results available

Intensity-Modulated Radiation Therapy, Cisplatin, and Bevacizumab Followed by Carboplatin and Paclitaxel in Treating Patients Who Have Undergone Surgery for Endometrial Cancer

NCT01005329
View directory record Official record
Conditions
Endometrial Adenocarcinoma, Endometrial Adenosquamous Carcinoma, Endometrial Clear Cell Adenocarcinoma, Endometrial Serous Adenocarcinoma, Stage IA Uterine Corpus Cancer AJCC v7, Stage IB Uterine Corpus Cancer AJCC v7, Stage II Uterine Corpus Cancer AJCC v7, Stage IIIA Uterine Corpus Cancer AJCC v7, Stage IIIB Uterine Corpus Cancer AJCC v7, Stage IIIC Uterine Corpus Cancer AJCC v7, Stage IVA Uterine Corpus Cancer AJCC v7, Stage IVB Uterine Corpus Cancer AJCC v7
Interventions
Bevacizumab, Carboplatin, Cisplatin, Intensity-Modulated Radiation Therapy, Paclitaxel
Biological · Drug · Radiation
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
38
States / cities
Berkeley, California • Walnut Creek, California • Colorado Springs, Colorado + 31 more
Source: ClinicalTrials.gov public record
Updated Mar 15, 2018 · Synced Oct 22, 2026, 10:24 PM EDT
Completed Not applicable Interventional Results available

St. Joe's Invitation Effectiveness Study

NCT04658888
View directory record Official record
Conditions
Cervical Cancer Screening
Interventions
Evalyn Self-Sampling Brush
Device
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
30 Years to 65 Years · Female only
Enrollment
964 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 6, 2022 · Synced Oct 22, 2026, 10:24 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Outcomes on Abdominal Versus Vaginal Morcellation At Time of Hysterectomy

NCT04434066
View directory record Official record
Conditions
Abnormal Uterine Bleeding, Uterine Bleeding, Fibroid Uterus, Surgery
Interventions
Total Laparoscopic Hysterectomy
Procedure
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
46 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2024
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Nov 8, 2024 · Synced Oct 22, 2026, 10:24 PM EDT
Not listed Phase 3 Interventional Accepts healthy volunteers

Prophylactic Tranexamic Acid During Minimally Invasive Myomectomies

NCT04311073
View directory record Official record
Conditions
Fibroid Uterus, Abnormal Uterine Bleeding, Myoma;Uterus
Interventions
Tranexamic Acid, Placebos
Drug
Lead sponsor
Eastern Virginia Medical School
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2024
U.S. locations
1
States / cities
Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Sep 11, 2023 · Synced Oct 22, 2026, 10:24 PM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

PSMA PET and MRI in Gynecological Cancers

NCT03302156
View directory record Official record
Conditions
Gynecologic Cancer
Interventions
PSMA-based 18F-DCFPyL PET tracer
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 99 Years · Female only
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Sep 5, 2023 · Synced Oct 22, 2026, 10:24 PM EDT
Completed Not applicable Interventional

The RECHARGE Low Carbohydrate Diet Trial for Metastatic Cancer

NCT00444054
View directory record Official record
Conditions
Cancer, Breast Cancer, Colon Cancer, Cervical Cancer, Uterine Cancer, Ovarian Cancer
Interventions
Very low carbohydrate diet (approximately 20 grams per day)
Behavioral
Lead sponsor
Albert Einstein College of Medicine
Other
Eligibility
21 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Oct 30, 2020 · Synced Oct 22, 2026, 10:24 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Effect of a Childcare Resource on Cervical Cancer Prevention

NCT06086054
View directory record Official record
Conditions
Cervical Dysplasia
Interventions
Navigation and EMR referral to childcare facility
Behavioral
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
65 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Aug 5, 2025 · Synced Oct 22, 2026, 10:24 PM EDT
Terminated Not applicable Interventional Results available

Feasibility - Beta Adrenergic Blockade (BB) in Cervical Cancer (CX)

NCT01902966
View directory record Official record
Conditions
Cervical Cancer
Interventions
Propranolol, Diary, Relaxation Audio Recording, Questionnaires
Drug · Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 12, 2021 · Synced Oct 22, 2026, 10:24 PM EDT
Terminated Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Positron Emission Tomography (PET) Imaging Studies With NIS Reporter

NCT02907073
View directory record Official record
Conditions
Myeloma, Endometrial Cancer
Interventions
BF4
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
21 Years and older
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 17, 2019 · Synced Oct 22, 2026, 10:24 PM EDT
Completed Phase 1 Interventional

A Study of XmAb®22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors

NCT03849469
View directory record Official record
Conditions
Melanoma, Cervical Carcinoma, Pancreatic Carcinoma, Triple Negative Breast Cancer, Hepatocellular Carcinoma, Urothelial Carcinoma, Squamous Cell Carcinoma of the Head and Neck, Nasopharyngeal Carcinoma, Renal Cell Carcinoma, Non-small Cell Lung Carcinoma, Small Cell Lung Carcinoma, Gastric or Gastroesophageal Junction Adenocarcinoma, Advanced or Metastatic Solid Tumors, Prostate Carcinoma, Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma, Intrahepatic Cholangiocarcinoma, Squamous Cell Anal Cancer, Squamous Cell Penile Carcinoma, Squamous Cell Vulvar Carcinoma, Colorectal Carcinoma, Endometrial Carcinoma
Interventions
XmAb®22841, Pembrolizumab (Keytruda®)
Biological
Lead sponsor
Xencor, Inc.
Industry
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
28
States / cities
Encinitas, California • La Jolla, California • Los Angeles, California + 15 more
Source: ClinicalTrials.gov public record
Updated Mar 30, 2023 · Synced Oct 22, 2026, 10:24 PM EDT
Not listed No phase listed Observational

Lynch Syndrome Can be Diagnosed Just From Somatic Mismatch Repair Mutation

NCT04516083
View directory record Official record
Conditions
Cancer Gene Mutation, Lynch Syndrome, Endometrial Cancer, Somatic Mutation
Interventions
Mismatch repair instability somatic and germline testing
Diagnostic Test
Lead sponsor
RWJ Barnabas Health at Jersey City Medical Center
Other
Eligibility
Female only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Jersey City, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 18, 2020 · Synced Oct 22, 2026, 10:24 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Low-Cost Molecular Cervical Cancer Screening Study

NCT01231945
View directory record Official record
Conditions
DNA Probes, E6 Protein, Uterine Cervical Neoplasms, HPV
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
25 Years to 65 Years · Female only
Enrollment
7,500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 22, 2026, 10:24 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Evidence-Based Approach to Empower Asian American Women in Cervical Cancer Screening

NCT04557423
View directory record Official record
Conditions
Uterine Cervical Neoplasms
Interventions
Community-Based Education, Navigation to Screening, HPV Self-Sampling
Behavioral
Lead sponsor
Fox Chase Cancer Center
Other
Eligibility
30 Years to 65 Years · Female only
Enrollment
797 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 24, 2026 · Synced Oct 22, 2026, 10:24 PM EDT
Completed Phase 2 Interventional

Combination Chemotherapy in Treating Patients With Recurrent or Refractory Cervical Cancer

NCT00002813
View directory record Official record
Conditions
Cervical Cancer
Interventions
cisplatin, vinorelbine tartrate
Drug
Lead sponsor
Gynecologic Oncology Group
Network
Eligibility
Female only
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1997
U.S. locations
9
States / cities
Orange, California • Honolulu, Hawaii • Baltimore, Maryland + 6 more
Source: ClinicalTrials.gov public record
Updated May 27, 2013 · Synced Oct 22, 2026, 10:24 PM EDT
Completed Not applicable Interventional

Caloric Restriction Before Surgery in Treating Patients With Endometrial, Prostate, or Breast Cancer

NCT02983279
View directory record Official record
Conditions
Breast Carcinoma, Endometrial Carcinoma, Prostate Carcinosarcoma
Interventions
Dietary Intervention, Counseling, Therapeutic
Dietary Supplement · Other · Procedure
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 29, 2025 · Synced Oct 22, 2026, 10:24 PM EDT
Recruiting Phase 2 Interventional

A Study of Ivonescimab in People With Endometrial and Cervical Cancers

NCT06925724
View directory record Official record
Conditions
Endometrial Cancer, Cervical Cancer
Interventions
Ivonescimab
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Oct 22, 2026, 10:24 PM EDT
Completed Phase 2 Interventional Results available

Study of LY3023414 for the Treatment of Recurrent or Persistent Endometrial Cancer

NCT02549989
View directory record Official record
Conditions
Endometrial Cancer, Recurrent Endometrial Cancer
Interventions
LY3023414
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
6
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Commack, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 22, 2023 · Synced Oct 22, 2026, 10:24 PM EDT
Completed Not applicable Interventional

Pelvic Floor Muscle Training in Treating Urinary Incontinence in Gynecologic Cancer Survivors

NCT01806350
View directory record Official record
Conditions
Cervical Cancer, Endometrial Cancer, Ovarian Epithelial Cancer, Ovarian Germ Cell Tumor, Uterine Sarcoma, Vulvar Cancer
Interventions
questionnaire administration, standard follow-up care, educational intervention
Other · Procedure
Lead sponsor
New Mexico Cancer Research Alliance
Other
Eligibility
30 Years and older · Female only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Mar 7, 2013 · Synced Oct 22, 2026, 10:24 PM EDT